Laboratoires Kelix

Kelix Bio is a specialty pharmaceutical group focused on providing high-quality, affordable specialty generic medicines and biosimilars to underserved markets across Africa and the Middle East. Founded in 2020, the company operates a robust manufacturing and distribution network with key facilities in Morocco, Tunisia, India, and Malta. Its portfolio primarily targets critical therapeutic areas including oncology, diabetes, and anti-infectives, aiming to reduce reliance on expensive imports. In March 2024, the company was acquired by Mubadala Investment Company, marking a significant step in enhancing pharmaceutical self-sufficiency in emerging regions. The group's strategy involves acquiring established local players and upgrading their capabilities to meet international GMP standards.